Anthrax vaccines: present status and future prospects
- PMID: 23984963
- DOI: 10.1586/14760584.2013.814860
Anthrax vaccines: present status and future prospects
Abstract
The management of anthrax remains a top priority among the biowarfare/bioterror agents. It was the Bacillus anthracis spore attack through the US mail system after the September 11, 2001, terrorist attacks in the USA that highlighted the potential of B. anthracis as a bioterrorism agent and the threat posed by its deliberate dissemination. These attacks invigorated the efforts toward understanding the anthrax pathogenesis and development of more comprehensive medical intervention strategies for its containment in case of both natural disease and manmade, accidental or deliberate infection of a non-suspecting population. Currently, efforts are directed toward the development of safe and efficacious vaccines as well as intervention tools for controlling the disease in the advanced fulminant stage when toxemia has already developed. This work presents an overview of the current understanding of anthrax pathogenesis and recent advances made, particularly after 2001, for the successful management of anthrax and outlines future perspectives.
Similar articles
-
Potential biological targets of Bacillus anthracis in anti-infective approaches against the threat of bioterrorism.Expert Rev Anti Infect Ther. 2007 Aug;5(4):665-84. doi: 10.1586/14787210.5.4.665. Expert Rev Anti Infect Ther. 2007. PMID: 17678429 Review.
-
Advances in the development of next-generation anthrax vaccines.Vaccine. 2009 Nov 5;27 Suppl 4:D28-32. doi: 10.1016/j.vaccine.2009.08.102. Vaccine. 2009. PMID: 19837282 Review.
-
Medical countermeasures to protect humans from anthrax bioterrorism.Trends Microbiol. 2009 Nov;17(11):522-8. doi: 10.1016/j.tim.2009.08.006. Epub 2009 Sep 24. Trends Microbiol. 2009. PMID: 19781945 Review.
-
The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics.J Infect Dis. 2007 Jan 15;195(2):174-84. doi: 10.1086/510312. Epub 2006 Dec 6. J Infect Dis. 2007. PMID: 17191162
-
[Selected research problems of anthrax vaccine development].Przegl Epidemiol. 2009;63(4):505-12. Przegl Epidemiol. 2009. PMID: 20120948 Review. Polish.
Cited by
-
Bacterial Toxins as Pathogen Weapons Against Phagocytes.Front Microbiol. 2016 Feb 1;7:42. doi: 10.3389/fmicb.2016.00042. eCollection 2016. Front Microbiol. 2016. PMID: 26870008 Free PMC article. Review.
-
Bacteriophage T4 as a Nanoparticle Platform to Display and Deliver Pathogen Antigens: Construction of an Effective Anthrax Vaccine.Methods Mol Biol. 2017;1581:255-267. doi: 10.1007/978-1-4939-6869-5_15. Methods Mol Biol. 2017. PMID: 28374254 Free PMC article.
-
Combination of poly I:C and Pam3CSK4 enhances activation of B cells in vitro and boosts antibody responses to protein vaccines in vivo.PLoS One. 2017 Jun 29;12(6):e0180073. doi: 10.1371/journal.pone.0180073. eCollection 2017. PLoS One. 2017. PMID: 28662082 Free PMC article.
-
A heterodimer of a VHH (variable domains of camelid heavy chain-only) antibody that inhibits anthrax toxin cell binding linked to a VHH antibody that blocks oligomer formation is highly protective in an anthrax spore challenge model.J Biol Chem. 2015 Mar 6;290(10):6584-95. doi: 10.1074/jbc.M114.627943. Epub 2015 Jan 6. J Biol Chem. 2015. PMID: 25564615 Free PMC article.
-
Development of a multiple-antigen protein fusion vaccine candidate that confers protection against Bacillus anthracis and Yersinia pestis.PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007644. doi: 10.1371/journal.pntd.0007644. eCollection 2019 Aug. PLoS Negl Trop Dis. 2019. PMID: 31430284 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical